Log in
Enquire now
‌

US Patent 11400099 Drug-induced epigenetic remodeling to prevent fibrosis

Patent 11400099 was granted and assigned to Thomas Jefferson University on August, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Thomas Jefferson University
Thomas Jefferson University
0
Current Assignee
Thomas Jefferson University
Thomas Jefferson University
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
114000990
Patent Inventor Names
A. Sue Menko0
Alexander Mazo0
Janice L. Walker0
Svetlana Petruk0
Date of Patent
August 2, 2022
0
Patent Application Number
163357160
Date Filed
September 25, 2017
0
Patent Citations Received
‌
US Patent 12083125 Drug-induced epigenetic remodeling to prevent fibrosis
0
Patent Primary Examiner
‌
Kara R McMillian
0
CPC Code
‌
A61K 9/0051
0
‌
A61K 9/0053
0
‌
A61K 9/00
0
‌
A61K 31/55
0
‌
C12Q 1/6883
0
‌
C12Q 2600/154
0
‌
A61P 11/00
0
‌
A61K 9/0014
0
...

A therapeutic treatment for preventing or reducing the formation of fibrosis comprising administering to a patient a UTX or JMJD3 inhibitor that are effective in preventing or reducing fibrosis in situations wherein access to an injury or dysmorphogenetic tissues before the fibrotic process becomes established in the tissues.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11400099 Drug-induced epigenetic remodeling to prevent fibrosis

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.